F2
F2 encodes Prothrombin, the precursor to Thrombin, the central enzyme of the blood clotting system. The Prothrombin G20210A variant is a major inherited risk factor for venous thrombosis, causing a gain-of-function increase in prothrombin levels.
Key Takeaways
- •Prothrombin is the raw material used to create Thrombin, the main builder of blood clots.
- •Thrombin converts liquid fibrinogen into solid fibrin "glue."
- •The G20210A variant (rs1799963) causes the body to produce too much prothrombin.
- •Carriers of the G20210A variant have a 2-3x higher risk of deep vein thrombosis.
Basic Information
- Gene Symbol
- F2
- Full Name
- Coagulation Factor II (Prothrombin)
- Also Known As
- PTFactor II
- Location
- 11p11.2
- Protein Type
- Serine Protease (Coagulation Factor)
- Protein Family
- Peptidase S1 family
Related Isoforms
Key SNPs
The Prothrombin G20210A variant. Increases the efficiency of mRNA processing, leading to higher plasma prothrombin levels and a significant increase in the risk of venous thromboembolism (VTE).
Common missense variant studied for its association with variations in prothrombin activity and risk of early-onset myocardial infarction.
Marker used in haplotype analysis of the F2 gene; associated with baseline variation in coagulation speed.
Overview
F2 encodes Prothrombin (Factor II), one of the most critical proteins in the human coagulation system. It circulates in the plasma as an inactive zymogen. When a blood vessel is damaged, the "clotting engine" (the prothrombinase complex) cleaves prothrombin into its active form: Thrombin. Thrombin is the definitive "master enzyme" of clotting, responsible for converting soluble fibrinogen into the solid fibrin mesh that seals a wound.
The biology of F2 is a study in "all-or-nothing" signaling. Because thrombin is so powerful, its production is kept in check by a series of complex feedback loops. Genetic variations in F2 that increase the baseline levels of prothrombin create a state of hypercoagulability, where the threshold for forming a dangerous blood clot is significantly lowered.
Conceptual Model
A simplified mental model for the pathway:
Thrombin is the "builder" that turns liquid blood into a solid defense.
Core Health Impacts
- • Clot Construction: Converts soluble fibrinogen into the structural fibrin threads of a clot
- • Platelet Activation: The most potent activator of platelets via PAR-1 receptors
- • Anticoagulant Switch: Paradoxically activates Protein C when bound to thrombomodulin to stop clotting
- • Thrombotic Risk: Primary genetic modifier of the risk for DVT and cerebral vein thrombosis
- • Inflammation: Acts as a signaling molecule that promotes vascular inflammation and remodeling
Protein Domains
Gla Domain
Vitamin K-dependent domain required for calcium-mediated binding to cell membranes.
Kringle Domains
Structural loops (K1, K2) that mediate protein-protein interactions within the clotting complex.
Serine Protease Domain
The catalytic heart of the protein that performs the enzymatic cleavage of fibrinogen and other factors.
Upstream Regulators
Factor Va Activator
The essential co-factor that anchors prothrombin to the platelet surface for activation.
Factor Xa Activator
The enzyme that physically cuts prothrombin to release active thrombin.
Calcium (Ca²⁺) Activator
Required for the Gla domain to "grasp" the phospholipid membrane during activation.
Vitamin K Activator
A required co-factor for the post-translational modification (gamma-carboxylation) of prothrombin.
Prothrombinase Complex Activator
The final quaternary complex (Xa, Va, Ca, PL) that is the definitive activator of F2.
Downstream Targets
Fibrinogen Activates
Cleaved by thrombin to produce fibrin monomers that polymerize into a clot.
Factors V, VIII, XI Activates
Thrombin activates these "upstream" factors in a positive feedback loop to amplify clotting.
Platelets (PAR1) Activates
Thrombin binds to Protease-Activated Receptors to trigger rapid platelet aggregation.
Protein C Activates
When bound to thrombomodulin, thrombin activates the Protein C "off-switch" for the system.
Factor XIII Activates
Activated by thrombin to cross-link fibrin threads, creating a stable, permanent clot.
Role in Aging
The F2/Thrombin system is a central mediator of "vascular aging." As the body ages, the baseline level of prothrombin activation increases, contributing to the "pro-thrombotic" environment of the elderly and increasing the risk of cardiovascular events.
Thrombin Burden
Aging is associated with higher "endogenous thrombin potential," making the elderly more sensitive to clotting triggers.
Vascular Remodeling
Thrombin signaling via PAR receptors drives the smooth muscle proliferation and arterial stiffening of aging.
Neurodegeneration Link
Excess thrombin in the brain, often due to micro-bleeds or BBB breakdown, is neurotoxic and linked to Alzheimer’s.
Inflammaging Hub
Thrombin is a potent pro-inflammatory signal; its chronic low-grade activation fuels systemic inflammaging.
Coagulation Drift
Age-related declines in natural anticoagulants (like Antithrombin III) remove the checks on F2 activity.
Stroke Risk
The cumulative risk of F2 gain-of-function variants peaks in late life as vascular health naturally declines.
Disorders & Diseases
Prothrombin G20210A
A common genetic variant (rs1799963) found in 2-3% of Caucasians. Causes higher prothrombin levels and a 2-3x increased risk of VTE.
Deep Vein Thrombosis (DVT)
The primary clinical manifestation of F2 risk variants, where clots form in the deep veins of the legs.
Cerebral Vein Thrombosis
A rare stroke type more strongly linked to the Prothrombin mutation than most other forms of thrombophilia.
Prothrombin Deficiency
Hypoprothrombinemia; a rare bleeding disorder characterized by poor clot formation and mucosal bleeding.
Pregnancy Complications
F2 risk variants are linked to placental infarction, preeclampsia, and recurrent early pregnancy loss.
Dysprothrombinemia
Conditions where the prothrombin protein is present but does not function correctly (e.g., Prothrombin Barcelona), causing a bleeding phenotype.
Interventions
Supplements
Essential for the "maturation" of the prothrombin protein; without it, the body makes "PIVKA" (inactive prothrombin).
May support healthy blood flow and modestly reduce the stickiness of platelets activated by thrombin.
Studied for its potential anti-thrombotic effects and ability to modulate thrombin-induced signaling.
Traditional support for vascular health reported to have mild anti-platelet and anti-clotting properties.
Lifestyle
Prevents the concentration of clotting factors (like prothrombin) that occurs during dehydration.
Essential during prolonged sitting to prevent the stasis that allows thrombin to build a clot in the veins.
Reduces the cytokine load that upregulates the liver's production of prothrombin.
Smoking damages the endothelium and triggers the release of tissue factor, the primary spark for F2 activation.
Medicines
Direct Thrombin Inhibitors (DTIs) that physically block the active site of the thrombin enzyme.
Catalyzes Antithrombin III to rapidly neutralize active thrombin and stop clot growth.
Vitamin K antagonist that stops the liver from producing functional Prothrombin (F2).
A potent thrombin inhibitor originally derived from leech saliva, used in specialized clinical settings.
Lab Tests & Biomarkers
Genetic Screening
Direct sequencing or PCR for the rs1799963 variant. Key for patients with personal or family history of DVT.
Assesses F2 variants alongside Factor V Leiden and Protein C/S levels.
Coagulation Speed
The standard test for the "extrinsic" pathway of clotting, heavily dependent on F2 levels.
Directly measures the time it takes for thrombin to convert fibrinogen to fibrin.
Activation Markers
A highly sensitive blood marker that indicates exactly how much prothrombin is being converted to thrombin.
Measures the rate of thrombin generation and subsequent neutralization by the body's natural brakes.
Hormonal Interactions
Estrogen Risk Factor
Increases the synthesis of prothrombin in the liver, synergizing with the G20210A mutation to elevate clot risk.
Progesterone Modulator
Has a milder effect on the clotting system than estrogen but is still monitored in high-risk thrombophilia.
Cortisol Upregulator
Acute stress can increase the availability of prothrombin as part of the body's ancient "wound-readiness" response.
Thyroid Hormone Modulator
Can influence the clearance rate of clotting factors and the sensitivity of the endothelium to thrombin.
Deep Dive
Network Diagrams
The Prothrombin Activation Sequence
The Master Architect: Prothrombin and Thrombin
To understand F2, one must view the clotting system as a massive construction project. While other factors are the laborers and tools, F2 (specifically the active form Thrombin) is the master architect.
The Zymogen Pool: Prothrombin is a zymogen—a dormant protein circulating in the blood. It waits for the “prothrombinase complex” (governed by Factor V and X) to give it the signal. Once two precise cuts are made in the prothrombin molecule, it is transformed into the active enzyme Thrombin.
The Multi-tool: Thrombin is the most versatile enzyme in the blood. Its primary job is to find liquid fibrinogen and turn it into solid fibrin. But it doesn’t stop there. It also travels back “upstream” to activate more Factor V and Factor VIII, essentially turning on its own fuel supply to ensure the wound is sealed as fast as possible.
The G20210A Variant: The Efficiency Mutation
The most important genetic variant in F2 is the rs1799963 (G20210A) mutation.
mRNA Stability: Unlike mutations that change the shape of a protein, the G20210A mutation happens in the “3’ untranslated region”—the part of the gene that handles instructions for how much protein to make. This mutation makes the mRNA more stable and more efficient at being read by the cell.
The Clinical Result: Individuals with this variant produce roughly 30% more prothrombin than average. In the “clotting engine,” this means there is always a surplus of raw material ready to be turned into thrombin. This surplus translates to a lifelong 2-to-3-fold increase in the risk of venous blood clots, making it one of the “big three” inherited thrombophilias along with Factor V Leiden and Protein C deficiency.
Beyond the Clot: Thrombin as a Signal
For decades, we thought thrombin was only about clotting. We now know it is a powerful signaling molecule that talks to the cells of the blood vessels and the brain.
PAR Receptors: Thrombin activates Protease-Activated Receptors (PARs) on the surface of platelets and endothelial cells. Through these receptors, thrombin can trigger inflammation, cause blood vessels to constrict, and even tell cells to divide.
The Double-Edged Sword: This signaling is vital for wound healing, but in the context of aging and chronic disease, too much thrombin signaling can be destructive. It is linked to the development of atherosclerotic plaques and may even contribute to neurodegeneration if it leaks into the brain. This makes F2 not just a “clotting gene,” but a major regulator of vascular and neurological “weather” throughout the human lifespan.
Practical Note: The Efficiency of the Engine
Supply vs. Demand. Prothrombin (F2) is the "supply" of clotting potential. In the G20210A carrier, the supply is always high. This doesn't mean they are clotting constantly, but it means that when a trigger (like surgery or injury) occurs, their "clotting engine" starts faster and builds a larger clot than a non-carrier.
Testing is proactive. Because the G20210A variant is a gain-of-function, it is easily managed with blood thinners if a clot occurs. The real value of testing is in prevention during high-risk times like pregnancy or recovery from major surgery.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The landmark study that first identified the G20210A mutation and its clinical significance in human disease.
Elucidated how the mutation increases mRNA stability and processing, explaining the gain-of-function effect.
Characterized the PAR receptors and established thrombin as a major signaling molecule beyond simple clotting.
Demonstrated that the basal rate of prothrombin activation increases with biological age.
Showed that F2 mutations are a particularly strong risk factor for rare forms of stroke in young adults.